Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II oral PHA-848125AC in previously treated thymic carcinoma
2009-014338-79Phase 2Completed
- Sponsor
- Nerviano Medical Sciences
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of milciclib in thymic carcinoma (TC), sponsored by Nerviano Medical Sciences. Primary endpoint: Progression-free survival rate at 3 months. Started Nov 2009; status: completed.
02
Drugs
milciclib
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on 2009-014338-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014338-79.